NO331977B1 - 2,4-di(fenylamino)pyrimidiner, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat innholdende en slik forbindelse - Google Patents

2,4-di(fenylamino)pyrimidiner, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat innholdende en slik forbindelse Download PDF

Info

Publication number: NO331977B1
Authority: NO; Norway
Prior art keywords: compound; formula; following table; substituted; set forth
Prior art date: 2003-03-14

Application number

NO20054726A

Other languages

English (en)

Norwegian (no)

Other versions

NO20054726D0 (no

NO20054726L (no

Inventor

Takanori Kanazawa

Naoko Matsuura

Osamu Ohmori

Ichiro Umemura

Carlos Garcia-Echeverria

Eiji Kawahara

Keiichi Masuya

Takahiro Miyake

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2005-10-13

Publication date

2012-05-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32995437&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO331977(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-08-15 Priority claimed from GB0319227A external-priority patent/GB0319227D0/en

2003-09-24 Priority claimed from GB0322370A external-priority patent/GB0322370D0/en

2005-10-13 Application filed by Novartis Ag filed Critical Novartis Ag

2005-10-13 Publication of NO20054726D0 publication Critical patent/NO20054726D0/no

2005-12-08 Publication of NO20054726L publication Critical patent/NO20054726L/no

2012-05-14 Publication of NO331977B1 publication Critical patent/NO331977B1/no

Links

238000002360 preparation method Methods 0.000 title claims abstract description 41
150000001875 compounds Chemical class 0.000 title claims description 212
238000000034 method Methods 0.000 title abstract description 43
239000008194 pharmaceutical composition Substances 0.000 title abstract description 9
GKFFFOLFBJUEFN-UHFFFAOYSA-N 2-n,4-n-diphenylpyrimidine-2,4-diamine Chemical class C=1C=NC(NC=2C=CC=CC=2)=NC=1NC1=CC=CC=C1 GKFFFOLFBJUEFN-UHFFFAOYSA-N 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 27
201000010099 disease Diseases 0.000 claims abstract description 18
208000026278 immune system disease Diseases 0.000 claims abstract description 7
230000001613 neoplastic effect Effects 0.000 claims abstract description 7
208000027866 inflammatory disease Diseases 0.000 claims abstract description 5
-1 hydroxy, amino, substituted amino Chemical group 0.000 claims description 91
229910052739 hydrogen Inorganic materials 0.000 claims description 45
239000001257 hydrogen Substances 0.000 claims description 45
150000003839 salts Chemical class 0.000 claims description 41
125000000623 heterocyclic group Chemical group 0.000 claims description 32
125000000217 alkyl group Chemical group 0.000 claims description 30
102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 claims description 29
108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 claims description 29
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 25
229910052736 halogen Inorganic materials 0.000 claims description 25
150000002367 halogens Chemical class 0.000 claims description 25
206010028980 Neoplasm Diseases 0.000 claims description 24
238000006243 chemical reaction Methods 0.000 claims description 24
150000002431 hydrogen Chemical class 0.000 claims description 20
125000001424 substituent group Chemical group 0.000 claims description 19
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 18
125000005842 heteroatom Chemical group 0.000 claims description 18
230000005764 inhibitory process Effects 0.000 claims description 17
239000004480 active ingredient Substances 0.000 claims description 16
239000000460 chlorine Substances 0.000 claims description 14
229910052760 oxygen Inorganic materials 0.000 claims description 14
229910052717 sulfur Inorganic materials 0.000 claims description 14
229920006395 saturated elastomer Polymers 0.000 claims description 13
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 12
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 12
125000004432 carbon atom Chemical group C* 0.000 claims description 11
125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 10
208000035475 disorder Diseases 0.000 claims description 9
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
229910052801 chlorine Inorganic materials 0.000 claims description 8
238000004519 manufacturing process Methods 0.000 claims description 8
230000001404 mediated effect Effects 0.000 claims description 7
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
230000002062 proliferating effect Effects 0.000 claims description 7
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
210000001744 T-lymphocyte Anatomy 0.000 claims description 6
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
229910052794 bromium Inorganic materials 0.000 claims description 6
229910052757 nitrogen Inorganic materials 0.000 claims description 6
UYJNQQDJUOUFQJ-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-morpholinyl)anilino]-4-pyrimidinyl]amino]-N-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Cl UYJNQQDJUOUFQJ-UHFFFAOYSA-N 0.000 claims description 5
125000003277 amino group Chemical group 0.000 claims description 5
125000005605 benzo group Chemical group 0.000 claims description 5
229910052799 carbon Inorganic materials 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 5
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 4
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 4
201000001441 melanoma Diseases 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
239000000825 pharmaceutical preparation Substances 0.000 claims description 4
210000002307 prostate Anatomy 0.000 claims description 4
210000001685 thyroid gland Anatomy 0.000 claims description 4
101100219283 Amycolatopsis orientalis cyp165C4 gene Proteins 0.000 claims description 3
208000023275 Autoimmune disease Diseases 0.000 claims description 3
206010025323 Lymphomas Diseases 0.000 claims description 3
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
210000003719 b-lymphocyte Anatomy 0.000 claims description 3
210000000481 breast Anatomy 0.000 claims description 3
210000003979 eosinophil Anatomy 0.000 claims description 3
125000005844 heterocyclyloxy group Chemical group 0.000 claims description 3
210000003630 histaminocyte Anatomy 0.000 claims description 3
210000002865 immune cell Anatomy 0.000 claims description 3
210000000987 immune system Anatomy 0.000 claims description 3
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
230000001537 neural effect Effects 0.000 claims description 3
201000008968 osteosarcoma Diseases 0.000 claims description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
BXFAKQVJYQDGLP-UHFFFAOYSA-N 2-[[5-bromo-2-(2,4-dimethoxyanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(OC)=CC=2)OC)=NC=C1Br BXFAKQVJYQDGLP-UHFFFAOYSA-N 0.000 claims description 2
UUHFFTGLLVVQKL-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-5-fluoro-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(F)=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Br UUHFFTGLLVVQKL-UHFFFAOYSA-N 0.000 claims description 2
125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 2
125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 2
206010020751 Hypersensitivity Diseases 0.000 claims description 2
102000038455 IGF Type 1 Receptor Human genes 0.000 claims description 2
108010031794 IGF Type 1 Receptor Proteins 0.000 claims description 2
206010052779 Transplant rejections Diseases 0.000 claims description 2
208000026935 allergic disease Diseases 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
125000004391 aryl sulfonyl group Chemical group 0.000 claims description 2
125000002837 carbocyclic group Chemical group 0.000 claims description 2
125000004093 cyano group Chemical group *C#N 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
210000004443 dendritic cell Anatomy 0.000 claims description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
210000003734 kidney Anatomy 0.000 claims description 2
210000004072 lung Anatomy 0.000 claims description 2
210000002540 macrophage Anatomy 0.000 claims description 2
125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 2
210000001672 ovary Anatomy 0.000 claims description 2
210000000496 pancreas Anatomy 0.000 claims description 2
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
ZWMDEVPYVGQJHU-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n,n-dimethylbenzenesulfonamide Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Br)C=1NC1=CC=CC=C1S(=O)(=O)N(C)C ZWMDEVPYVGQJHU-UHFFFAOYSA-N 0.000 claims 1
JHMBTUMIVBSJFS-UHFFFAOYSA-N 2-methyl-3h-isoindol-1-one Chemical compound C1=CC=C2C(=O)N(C)CC2=C1 JHMBTUMIVBSJFS-UHFFFAOYSA-N 0.000 claims 1
125000004429 atom Chemical group 0.000 claims 1
230000002496 gastric effect Effects 0.000 claims 1
230000002757 inflammatory effect Effects 0.000 abstract description 6
239000008177 pharmaceutical agent Substances 0.000 abstract description 3
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 abstract description 2
150000003230 pyrimidines Chemical class 0.000 abstract description 2
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 198
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 110
239000000203 mixture Substances 0.000 description 76
239000000243 solution Substances 0.000 description 65
235000019439 ethyl acetate Nutrition 0.000 description 62
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 49
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 48
210000004027 cell Anatomy 0.000 description 44
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
235000002639 sodium chloride Nutrition 0.000 description 42
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
239000007787 solid Substances 0.000 description 33
238000005160 1H NMR spectroscopy Methods 0.000 description 32
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 31
239000012044 organic layer Substances 0.000 description 28
239000012267 brine Substances 0.000 description 27
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
102100033793 ALK tyrosine kinase receptor Human genes 0.000 description 24
101710168331 ALK tyrosine kinase receptor Proteins 0.000 description 24
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 22
239000011541 reaction mixture Substances 0.000 description 22
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
229910052938 sodium sulfate Inorganic materials 0.000 description 18
235000011152 sodium sulphate Nutrition 0.000 description 18
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
238000010898 silica gel chromatography Methods 0.000 description 16
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
238000005481 NMR spectroscopy Methods 0.000 description 15
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
238000012360 testing method Methods 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
230000000694 effects Effects 0.000 description 14
239000000725 suspension Substances 0.000 description 14
108091003079 Bovine Serum Albumin Proteins 0.000 description 13
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
239000003112 inhibitor Substances 0.000 description 13
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
239000002253 acid Substances 0.000 description 11
238000001914 filtration Methods 0.000 description 11
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
239000011780 sodium chloride Substances 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 9
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 9
229940098773 bovine serum albumin Drugs 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
229910052943 magnesium sulfate Inorganic materials 0.000 description 9
235000019341 magnesium sulphate Nutrition 0.000 description 9
229910000027 potassium carbonate Inorganic materials 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
238000001816 cooling Methods 0.000 description 8
239000002244 precipitate Substances 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
238000003756 stirring Methods 0.000 description 8
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 7
102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 7
108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 7
239000002299 complementary DNA Substances 0.000 description 7
230000012010 growth Effects 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
239000000047 product Substances 0.000 description 7
230000009467 reduction Effects 0.000 description 7
239000002904 solvent Substances 0.000 description 7
ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 6
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 6
239000007995 HEPES buffer Substances 0.000 description 6
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 6
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 6
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
241000699666 Mus <mouse, genus> Species 0.000 description 6
229920001213 Polysorbate 20 Polymers 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000000706 filtrate Substances 0.000 description 6
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
229910000041 hydrogen chloride Inorganic materials 0.000 description 6
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
238000011534 incubation Methods 0.000 description 6
239000002609 medium Substances 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
229920001223 polyethylene glycol Chemical class 0.000 description 6
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 6
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
235000018102 proteins Nutrition 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
229910000104 sodium hydride Inorganic materials 0.000 description 6
239000000758 substrate Substances 0.000 description 6
238000005406 washing Methods 0.000 description 6
HCPLJTFWHJREKI-UHFFFAOYSA-N 2-[(5-bromo-2-chloropyrimidin-4-yl)amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Br HCPLJTFWHJREKI-UHFFFAOYSA-N 0.000 description 5
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
SSEZSHJJNNLTQI-UHFFFAOYSA-N 2-amino-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1N SSEZSHJJNNLTQI-UHFFFAOYSA-N 0.000 description 5
101150041968 CDC13 gene Proteins 0.000 description 5
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 5
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
235000014113 dietary fatty acids Nutrition 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
239000000284 extract Substances 0.000 description 5
239000000194 fatty acid Substances 0.000 description 5
229930195729 fatty acid Natural products 0.000 description 5
239000000543 intermediate Substances 0.000 description 5
238000000021 kinase assay Methods 0.000 description 5
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
239000002953 phosphate buffered saline Substances 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
125000006239 protecting group Chemical group 0.000 description 5
238000010992 reflux Methods 0.000 description 5
239000012312 sodium hydride Substances 0.000 description 5
239000007858 starting material Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 4
LUJRXBPJCKLPLU-UHFFFAOYSA-N 4-(4-methoxyphenyl)-1-methyl-2-nitrobenzene Chemical group C1=CC(OC)=CC=C1C1=CC=C(C)C([N+]([O-])=O)=C1 LUJRXBPJCKLPLU-UHFFFAOYSA-N 0.000 description 4
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
KZNXALJXBRSMFL-UHFFFAOYSA-N 4-bromo-1-methyl-2-nitrobenzene Chemical compound CC1=CC=C(Br)C=C1[N+]([O-])=O KZNXALJXBRSMFL-UHFFFAOYSA-N 0.000 description 4
102000002260 Alkaline Phosphatase Human genes 0.000 description 4
108020004774 Alkaline Phosphatase Proteins 0.000 description 4
108020004414 DNA Proteins 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 4
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
229940124783 FAK inhibitor Drugs 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
108091000080 Phosphotransferase Proteins 0.000 description 4
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
239000002202 Polyethylene glycol Chemical class 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
235000019270 ammonium chloride Nutrition 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
230000035578 autophosphorylation Effects 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
238000001514 detection method Methods 0.000 description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
238000002866 fluorescence resonance energy transfer Methods 0.000 description 4
125000005456 glyceride group Chemical group 0.000 description 4
238000000338 in vitro Methods 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
239000007788 liquid Substances 0.000 description 4
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
102000020233 phosphotransferase Human genes 0.000 description 4
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
239000001267 polyvinylpyrrolidone Substances 0.000 description 4
229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
235000012222 talc Nutrition 0.000 description 4
229940100445 wheat starch Drugs 0.000 description 4
GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 3
NRPNUOKRHRYIBP-UHFFFAOYSA-N 2-[(2,5-dichloropyrimidin-4-yl)amino]-n-methylbenzamide Chemical compound CNC(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl NRPNUOKRHRYIBP-UHFFFAOYSA-N 0.000 description 3
FLHSVHDSGAKTQZ-UHFFFAOYSA-N 2-methyl-7-nitro-3h-isoindol-1-one Chemical compound C1=CC([N+]([O-])=O)=C2C(=O)N(C)CC2=C1 FLHSVHDSGAKTQZ-UHFFFAOYSA-N 0.000 description 3
WLKUSVNHZXUEFO-UHFFFAOYSA-N 4-fluoro-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(F)=CC=C1[N+]([O-])=O WLKUSVNHZXUEFO-UHFFFAOYSA-N 0.000 description 3
SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 3
JPARDNRMCTVFJO-UHFFFAOYSA-N 7-amino-2-methyl-3h-isoindol-1-one Chemical compound C1=CC(N)=C2C(=O)N(C)CC2=C1 JPARDNRMCTVFJO-UHFFFAOYSA-N 0.000 description 3
239000005711 Benzoic acid Substances 0.000 description 3
208000026310 Breast neoplasm Diseases 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
101000878536 Homo sapiens Focal adhesion kinase 1 Proteins 0.000 description 3
108010002386 Interleukin-3 Proteins 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
KIMWOULVHFLJIU-UHFFFAOYSA-N N-Methylanthranilamide Chemical compound CNC(=O)C1=CC=CC=C1N KIMWOULVHFLJIU-UHFFFAOYSA-N 0.000 description 3
229910020700 Na3VO4 Inorganic materials 0.000 description 3
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000012317 TBTU Substances 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
235000001014 amino acid Nutrition 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
230000001028 anti-proliverative effect Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
239000012298 atmosphere Substances 0.000 description 3
201000008275 breast carcinoma Diseases 0.000 description 3
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
229910000024 caesium carbonate Inorganic materials 0.000 description 3
239000002775 capsule Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000000576 coating method Methods 0.000 description 3
CNXMDTWQWLGCPE-UHFFFAOYSA-N ditert-butyl-(2-phenylphenyl)phosphane Chemical group CC(C)(C)P(C(C)(C)C)C1=CC=CC=C1C1=CC=CC=C1 CNXMDTWQWLGCPE-UHFFFAOYSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000012091 fetal bovine serum Substances 0.000 description 3
239000012894 fetal calf serum Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
102000057090 human PTK2 Human genes 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000002198 insoluble material Substances 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
239000010410 layer Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
238000002156 mixing Methods 0.000 description 3
LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 3
YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
235000011007 phosphoric acid Nutrition 0.000 description 3
230000026731 phosphorylation Effects 0.000 description 3
238000006366 phosphorylation reaction Methods 0.000 description 3
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
229920000053 polysorbate 80 Polymers 0.000 description 3
238000000746 purification Methods 0.000 description 3
150000003254 radicals Chemical class 0.000 description 3
238000003757 reverse transcription PCR Methods 0.000 description 3
238000000926 separation method Methods 0.000 description 3
230000019491 signal transduction Effects 0.000 description 3
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
239000013598 vector Substances 0.000 description 3
125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 2
SNYOQELAUCYAKA-UHFFFAOYSA-N 1-(3-methoxy-4-nitrophenyl)piperidin-4-ol Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2CCC(O)CC2)=C1 SNYOQELAUCYAKA-UHFFFAOYSA-N 0.000 description 2
VWVGKNTWOBCSTI-UHFFFAOYSA-N 1-(3-methoxy-4-nitrophenyl)piperidin-4-one Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(N2CCC(=O)CC2)=C1 VWVGKNTWOBCSTI-UHFFFAOYSA-N 0.000 description 2
FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 2
RXIKYXZKSIARLN-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxol-4-amine Chemical compound NC1=CC=CC2=C1OC(F)(F)O2 RXIKYXZKSIARLN-UHFFFAOYSA-N 0.000 description 2
INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 2
WVZJQAUQBXFQMJ-UHFFFAOYSA-N 2-[(2,5-dichloropyrimidin-4-yl)amino]-5-fluoro-n-methylbenzamide Chemical compound CNC(=O)C1=CC(F)=CC=C1NC1=NC(Cl)=NC=C1Cl WVZJQAUQBXFQMJ-UHFFFAOYSA-N 0.000 description 2
LUVNLXYMPRWSHP-UHFFFAOYSA-N 2-[(2-chloro-5-nitropyrimidin-4-yl)amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1[N+]([O-])=O LUVNLXYMPRWSHP-UHFFFAOYSA-N 0.000 description 2
RUFFLJJHBSVJRD-UHFFFAOYSA-N 2-[(5-bromo-2-chloropyrimidin-4-yl)amino]benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Br RUFFLJJHBSVJRD-UHFFFAOYSA-N 0.000 description 2
OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical compound OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 description 2
VNIOEOSEBKVWDI-UHFFFAOYSA-N 2-[[2-chloro-5-(trifluoromethyl)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1C(F)(F)F VNIOEOSEBKVWDI-UHFFFAOYSA-N 0.000 description 2
WGAROJNINOOTKS-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]benzoic acid Chemical compound COC1=CC(N2CCOCC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1C(O)=O WGAROJNINOOTKS-UHFFFAOYSA-N 0.000 description 2
WBUGAGVKLSBBGG-UHFFFAOYSA-N 2-amino-5-fluoro-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(F)=CC=C1N WBUGAGVKLSBBGG-UHFFFAOYSA-N 0.000 description 2
STQMIAZPBHMUEK-UHFFFAOYSA-N 2-methoxy-4-morpholin-4-ylaniline;dihydrochloride Chemical compound Cl.Cl.C1=C(N)C(OC)=CC(N2CCOCC2)=C1 STQMIAZPBHMUEK-UHFFFAOYSA-N 0.000 description 2
NBJHDLKSWUDGJG-UHFFFAOYSA-N 4-(2-chloroethyl)morpholin-4-ium;chloride Chemical compound Cl.ClCCN1CCOCC1 NBJHDLKSWUDGJG-UHFFFAOYSA-N 0.000 description 2
CYMDJHMDVUTLRA-UHFFFAOYSA-N 4-(4-methyl-3-nitrophenyl)morpholine Chemical compound C1=C([N+]([O-])=O)C(C)=CC=C1N1CCOCC1 CYMDJHMDVUTLRA-UHFFFAOYSA-N 0.000 description 2
AADXAMFLYDYIFS-UHFFFAOYSA-N 4-methoxy-3-nitrophenol Chemical compound COC1=CC=C(O)C=C1[N+]([O-])=O AADXAMFLYDYIFS-UHFFFAOYSA-N 0.000 description 2
BBEWSMNRCUXQRF-UHFFFAOYSA-N 4-methyl-3-nitrobenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1[N+]([O-])=O BBEWSMNRCUXQRF-UHFFFAOYSA-N 0.000 description 2
BYDZPWGZEBVUKE-UHFFFAOYSA-N 7-[(2,5-dichloropyrimidin-4-yl)amino]-2-methyl-3h-isoindol-1-one Chemical compound C=12C(=O)N(C)CC2=CC=CC=1NC1=NC(Cl)=NC=C1Cl BYDZPWGZEBVUKE-UHFFFAOYSA-N 0.000 description 2
206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010006187 Breast cancer Diseases 0.000 description 2
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
208000002699 Digestive System Neoplasms Diseases 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
101100015729 Drosophila melanogaster drk gene Proteins 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
108010093488 His-His-His-His-His-His Proteins 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 2
229910021380 Manganese Chloride Inorganic materials 0.000 description 2
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 description 2
239000007832 Na2SO4 Substances 0.000 description 2
102100022678 Nucleophosmin Human genes 0.000 description 2
108010025568 Nucleophosmin Proteins 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
PBBRWFOVCUAONR-UHFFFAOYSA-N PP2 Chemical compound C12=C(N)N=CN=C2N(C(C)(C)C)N=C1C1=CC=C(Cl)C=C1 PBBRWFOVCUAONR-UHFFFAOYSA-N 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
239000012083 RIPA buffer Substances 0.000 description 2
235000021355 Stearic acid Nutrition 0.000 description 2
108010090804 Streptavidin Proteins 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
208000024770 Thyroid neoplasm Diseases 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
238000006136 alcoholysis reaction Methods 0.000 description 2
108010004469 allophycocyanin Proteins 0.000 description 2
229910000147 aluminium phosphate Inorganic materials 0.000 description 2
VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
150000001448 anilines Chemical class 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
AILAQOYFPLQIFN-UHFFFAOYSA-N butyl piperazine-1-carboxylate Chemical compound CCCCOC(=O)N1CCNCC1 AILAQOYFPLQIFN-UHFFFAOYSA-N 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
230000009087 cell motility Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000004440 column chromatography Methods 0.000 description 2
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
229960004397 cyclophosphamide Drugs 0.000 description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000013024 dilution buffer Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 2
OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
230000005284 excitation Effects 0.000 description 2
239000000945 filler Substances 0.000 description 2
238000011049 filling Methods 0.000 description 2
238000003818 flash chromatography Methods 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000012634 fragment Substances 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
101150098203 grb2 gene Proteins 0.000 description 2
229940093915 gynecological organic acid Drugs 0.000 description 2
239000007902 hard capsule Substances 0.000 description 2
230000002489 hematologic effect Effects 0.000 description 2
KEMQGTRYUADPNZ-UHFFFAOYSA-N heptadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(O)=O KEMQGTRYUADPNZ-UHFFFAOYSA-N 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
VKOBVWXKNCXXDE-UHFFFAOYSA-N icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCC(O)=O VKOBVWXKNCXXDE-UHFFFAOYSA-N 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
230000001506 immunosuppresive effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000012417 linear regression Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
238000012792 lyophilization process Methods 0.000 description 2
239000006166 lysate Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
239000011565 manganese chloride Substances 0.000 description 2
235000002867 manganese chloride Nutrition 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 2
VFYDKBLWXIWGJU-UHFFFAOYSA-N n-butan-2-yl-2-[(2,5-dichloropyrimidin-4-yl)amino]benzenesulfonamide Chemical compound CCC(C)NS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl VFYDKBLWXIWGJU-UHFFFAOYSA-N 0.000 description 2
XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 description 2
BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
235000005985 organic acids Nutrition 0.000 description 2
NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
238000003118 sandwich ELISA Methods 0.000 description 2
230000011664 signaling Effects 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
239000007901 soft capsule Substances 0.000 description 2
238000003797 solvolysis reaction Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008117 stearic acid Substances 0.000 description 2
239000011550 stock solution Substances 0.000 description 2
TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
239000000126 substance Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
LIDMYQRDZLWVQQ-UHFFFAOYSA-N tert-butyl 4-(3-amino-4-methylbenzoyl)piperazine-1-carboxylate Chemical compound C1=C(N)C(C)=CC=C1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1 LIDMYQRDZLWVQQ-UHFFFAOYSA-N 0.000 description 2
YOLGTRLHPOVFHT-UHFFFAOYSA-N tert-butyl 4-(4-methyl-3-nitrobenzoyl)piperazine-1-carboxylate Chemical compound C1=C([N+]([O-])=O)C(C)=CC=C1C(=O)N1CCN(C(=O)OC(C)(C)C)CC1 YOLGTRLHPOVFHT-UHFFFAOYSA-N 0.000 description 2
125000003831 tetrazolyl group Chemical group 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
150000003626 triacylglycerols Chemical class 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
208000025421 tumor of uterus Diseases 0.000 description 2
238000010518 undesired secondary reaction Methods 0.000 description 2
206010046766 uterine cancer Diseases 0.000 description 2
238000001262 western blot Methods 0.000 description 2
229910052727 yttrium Inorganic materials 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
OIOAKXPMBIZAHL-LURJTMIESA-N (2s)-2-azaniumyl-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoate Chemical compound CC(C)(C)OC(=O)CC[C@H](N)C(O)=O OIOAKXPMBIZAHL-LURJTMIESA-N 0.000 description 1
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
XUZGGGXQVSZPDD-UHFFFAOYSA-N (4-methoxy-3-nitrophenyl) acetate Chemical compound COC1=CC=C(OC(C)=O)C=C1[N+]([O-])=O XUZGGGXQVSZPDD-UHFFFAOYSA-N 0.000 description 1
SXLHAMYMTUEALX-UHFFFAOYSA-N (4-methoxyphenoxy)boronic acid Chemical compound COC1=CC=C(OB(O)O)C=C1 SXLHAMYMTUEALX-UHFFFAOYSA-N 0.000 description 1
VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000004607 1,2,3,4-tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 1
GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 1
KJWHJDGMOQJLGF-UHFFFAOYSA-N 1-methylsulfanyldodecane Chemical compound CCCCCCCCCCCCSC KJWHJDGMOQJLGF-UHFFFAOYSA-N 0.000 description 1
PKDPUENCROCRCH-UHFFFAOYSA-N 1-piperazin-1-ylethanone Chemical compound CC(=O)N1CCNCC1 PKDPUENCROCRCH-UHFFFAOYSA-N 0.000 description 1
125000006017 1-propenyl group Chemical group 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 1
GEQNZVKIDIPGCO-UHFFFAOYSA-N 2,4-dimethoxyaniline Chemical compound COC1=CC=C(N)C(OC)=C1 GEQNZVKIDIPGCO-UHFFFAOYSA-N 0.000 description 1
ZBIGXRRIWFOTQE-UHFFFAOYSA-N 2,5-dichloro-n-(2-ethylsulfonylphenyl)pyrimidin-4-amine Chemical compound CCS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl ZBIGXRRIWFOTQE-UHFFFAOYSA-N 0.000 description 1
WWVLDJAVSQZSKO-UHFFFAOYSA-N 2,5-dichloro-n-(2-propan-2-ylsulfonylphenyl)pyrimidin-4-amine Chemical compound CC(C)S(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl WWVLDJAVSQZSKO-UHFFFAOYSA-N 0.000 description 1
ROWNOQSMBAURLR-UHFFFAOYSA-N 2,5-dichloro-n-(2-propylsulfonylphenyl)pyrimidin-4-amine Chemical compound CCCS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl ROWNOQSMBAURLR-UHFFFAOYSA-N 0.000 description 1
NAZDVUBIEPVUKE-UHFFFAOYSA-N 2,5-dimethoxyaniline Chemical compound COC1=CC=C(OC)C(N)=C1 NAZDVUBIEPVUKE-UHFFFAOYSA-N 0.000 description 1
XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
GISTXBCQAPHMEB-UHFFFAOYSA-N 2-[(2,5-dichloropyrimidin-4-yl)amino]-n,6-dimethylbenzamide Chemical compound CNC(=O)C1=C(C)C=CC=C1NC1=NC(Cl)=NC=C1Cl GISTXBCQAPHMEB-UHFFFAOYSA-N 0.000 description 1
ALNPXJKDQKRBSU-UHFFFAOYSA-N 2-[(2,5-dichloropyrimidin-4-yl)amino]-n-ethylbenzamide Chemical compound CCNC(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl ALNPXJKDQKRBSU-UHFFFAOYSA-N 0.000 description 1
CUBHDXYOAVGZNN-UHFFFAOYSA-N 2-[(2,5-dichloropyrimidin-4-yl)amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl CUBHDXYOAVGZNN-UHFFFAOYSA-N 0.000 description 1
RVWJXUPKHRWGDM-UHFFFAOYSA-N 2-[(2,5-dichloropyrimidin-4-yl)amino]-n-pentan-3-ylbenzenesulfonamide Chemical compound CCC(CC)NS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl RVWJXUPKHRWGDM-UHFFFAOYSA-N 0.000 description 1
WSXNRMJFCZFMDC-UHFFFAOYSA-N 2-[(2,5-dichloropyrimidin-4-yl)amino]-n-propan-2-ylbenzenesulfonamide Chemical compound CC(C)NS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Cl WSXNRMJFCZFMDC-UHFFFAOYSA-N 0.000 description 1
ZZNNUEGPGLUOEE-UHFFFAOYSA-N 2-[(5-bromo-2-chloropyrimidin-4-yl)amino]-5-fluoro-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(F)=CC=C1NC1=NC(Cl)=NC=C1Br ZZNNUEGPGLUOEE-UHFFFAOYSA-N 0.000 description 1
QCGRFJPJEZWMFM-UHFFFAOYSA-N 2-[(5-bromo-2-chloropyrimidin-4-yl)amino]-n-propylbenzenesulfonamide Chemical compound CCCNS(=O)(=O)C1=CC=CC=C1NC1=NC(Cl)=NC=C1Br QCGRFJPJEZWMFM-UHFFFAOYSA-N 0.000 description 1
NWJPJGHTHAAJLR-UHFFFAOYSA-N 2-[(5-chloro-2-methylpyrimidin-4-yl)amino]-n-methyl-5-pyrrolidin-1-ylbenzamide Chemical compound CNC(=O)C1=CC(N2CCCC2)=CC=C1NC1=NC(C)=NC=C1Cl NWJPJGHTHAAJLR-UHFFFAOYSA-N 0.000 description 1
YSDPMNWDZMLLLK-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCOCC2)OC)=NC=C1Br YSDPMNWDZMLLLK-UHFFFAOYSA-N 0.000 description 1
UWMGQQWDXJETSN-UHFFFAOYSA-N 2-[[5-bromo-2-(2-methoxy-5-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(C=2)N2CCOCC2)OC)=NC=C1Br UWMGQQWDXJETSN-UHFFFAOYSA-N 0.000 description 1
IVIVGPYDZNRLFP-UHFFFAOYSA-N 2-[[5-bromo-2-(5-fluoro-2-methoxyanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC=C(F)C=2)OC)=NC=C1Br IVIVGPYDZNRLFP-UHFFFAOYSA-N 0.000 description 1
NYFKGGZMHOQQBX-UHFFFAOYSA-N 2-[[5-chloro-2-(2-methoxy-4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCNCC2)OC)=NC=C1Cl NYFKGGZMHOQQBX-UHFFFAOYSA-N 0.000 description 1
PRYDBAILIFDCPN-UHFFFAOYSA-N 2-[[5-chloro-2-(5-fluoro-2-methoxyanilino)pyrimidin-4-yl]amino]-n-(2-methylpropyl)benzenesulfonamide Chemical compound COC1=CC=C(F)C=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)S(=O)(=O)NCC(C)C)=N1 PRYDBAILIFDCPN-UHFFFAOYSA-N 0.000 description 1
UIURJGHFUQVQKB-UHFFFAOYSA-N 2-[[5-chloro-2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound COC1=CC(N2CCN(C)CC2)=CC=C1NC(N=1)=NC=C(Cl)C=1NC1=CC=CC=C1S(=O)(=O)NC(C)C UIURJGHFUQVQKB-UHFFFAOYSA-N 0.000 description 1
IWBUGKWDHWHLCF-UHFFFAOYSA-N 2-[[5-chloro-2-[4-[3-(methylamino)pyrrolidin-1-yl]anilino]pyrimidin-4-yl]amino]-n-propan-2-ylbenzenesulfonamide Chemical compound C1C(NC)CCN1C(C=C1)=CC=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)S(=O)(=O)NC(C)C)=N1 IWBUGKWDHWHLCF-UHFFFAOYSA-N 0.000 description 1
VYZCFAPUHSSYCC-UHFFFAOYSA-N 2-amino-5-chloro-4-methylbenzenesulfonic acid Chemical compound CC1=CC(N)=C(S(O)(=O)=O)C=C1Cl VYZCFAPUHSSYCC-UHFFFAOYSA-N 0.000 description 1
WCKGIIFMLKFXOS-UHFFFAOYSA-N 2-amino-5-chloro-n,4-dimethylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC(Cl)=C(C)C=C1N WCKGIIFMLKFXOS-UHFFFAOYSA-N 0.000 description 1
PFMDLZQSUMZMHZ-UHFFFAOYSA-N 2-amino-n-propan-2-ylbenzenesulfonamide Chemical compound CC(C)NS(=O)(=O)C1=CC=CC=C1N PFMDLZQSUMZMHZ-UHFFFAOYSA-N 0.000 description 1
FFEGBNMXZXUZSA-UHFFFAOYSA-N 2-amino-n-propylbenzenesulfonamide Chemical compound CCCNS(=O)(=O)C1=CC=CC=C1N FFEGBNMXZXUZSA-UHFFFAOYSA-N 0.000 description 1
YAZSBRQTAHVVGE-UHFFFAOYSA-N 2-aminobenzenesulfonamide Chemical compound NC1=CC=CC=C1S(N)(=O)=O YAZSBRQTAHVVGE-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
XTWVCSNXEQMXKX-UHFFFAOYSA-N 2-methoxy-4-(1-methylpiperidin-4-yl)oxyaniline Chemical compound C1=C(N)C(OC)=CC(OC2CCN(C)CC2)=C1 XTWVCSNXEQMXKX-UHFFFAOYSA-N 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
125000005975 2-phenylethyloxy group Chemical group 0.000 description 1
125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
YEYKMVJDLWJFOA-UHFFFAOYSA-N 2-propoxyethanol Chemical compound CCCOCCO YEYKMVJDLWJFOA-UHFFFAOYSA-N 0.000 description 1
DEQVKVCODPHASQ-UHFFFAOYSA-N 2-propylsulfonylaniline Chemical compound CCCS(=O)(=O)C1=CC=CC=C1N DEQVKVCODPHASQ-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
CSSGKHVRDGATJL-UHFFFAOYSA-N 3-fluoro-4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C(F)=C1 CSSGKHVRDGATJL-UHFFFAOYSA-N 0.000 description 1
125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
VDQSACYMBGQMFC-UHFFFAOYSA-N 3-methoxy-4-nitrophenol Chemical compound COC1=CC(O)=CC=C1[N+]([O-])=O VDQSACYMBGQMFC-UHFFFAOYSA-N 0.000 description 1
ZZDMRKSFGGRJHT-UHFFFAOYSA-N 4-(2-methoxyethoxy)-1-(3-methoxy-4-nitrophenyl)piperidine Chemical compound C1CC(OCCOC)CCN1C1=CC=C([N+]([O-])=O)C(OC)=C1 ZZDMRKSFGGRJHT-UHFFFAOYSA-N 0.000 description 1
PXBHUMZNOGYDAD-UHFFFAOYSA-N 4-(3-methoxy-4-nitrophenoxy)-1-methylpiperidine Chemical compound C1=C([N+]([O-])=O)C(OC)=CC(OC2CCN(C)CC2)=C1 PXBHUMZNOGYDAD-UHFFFAOYSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
DJKPQYBFSAJUBS-UHFFFAOYSA-N 4-bromo-2-methoxy-1-nitrobenzene Chemical compound COC1=CC(Br)=CC=C1[N+]([O-])=O DJKPQYBFSAJUBS-UHFFFAOYSA-N 0.000 description 1
229960000549 4-dimethylaminophenol Drugs 0.000 description 1
WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
AIROINZDCGLJBZ-UHFFFAOYSA-N 5-(4-methoxyphenyl)-2-methylaniline Chemical group C1=CC(OC)=CC=C1C1=CC=C(C)C(N)=C1 AIROINZDCGLJBZ-UHFFFAOYSA-N 0.000 description 1
ZDCPYKDNLZEPSX-UHFFFAOYSA-N 5-chloro-2-n-[2-methoxy-4-(4-piperidin-1-ylpiperidin-1-yl)phenyl]-4-n-(2-propylsulfonylphenyl)pyrimidine-2,4-diamine Chemical compound CCCS(=O)(=O)C1=CC=CC=C1NC1=NC(NC=2C(=CC(=CC=2)N2CCC(CC2)N2CCCCC2)OC)=NC=C1Cl ZDCPYKDNLZEPSX-UHFFFAOYSA-N 0.000 description 1
INMIEUQKQXVBKR-UHFFFAOYSA-N 7,8-dihydro-6h-cyclohepta[b]pyridine-5,9-dione Chemical compound O=C1CCCC(=O)C2=NC=CC=C12 INMIEUQKQXVBKR-UHFFFAOYSA-N 0.000 description 1
ZQRUARXOXMJFPQ-UHFFFAOYSA-N 7-[(2,5-dichloropyrimidin-4-yl)amino]-2-ethyl-3h-isoindol-1-one Chemical compound C=12C(=O)N(CC)CC2=CC=CC=1NC1=NC(Cl)=NC=C1Cl ZQRUARXOXMJFPQ-UHFFFAOYSA-N 0.000 description 1
YAEBIFUNMFGUNU-UHFFFAOYSA-N 7-[(4-amino-2,5-dichloro-1h-pyrimidin-4-yl)amino]-2-methyl-3h-isoindol-1-one Chemical compound C=12C(=O)N(C)CC2=CC=CC=1NC1(N)NC(Cl)=NC=C1Cl YAEBIFUNMFGUNU-UHFFFAOYSA-N 0.000 description 1
UJEUDJUGBOMEOQ-UHFFFAOYSA-N 7-[[5-chloro-2-(2-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]amino]-2-methyl-3h-isoindol-1-one Chemical compound C=1C=C(NC=2N=C(NC=3C=4C(=O)N(C)CC=4C=CC=3)C(Cl)=CN=2)C(OC)=CC=1N1CCOCC1 UJEUDJUGBOMEOQ-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical group CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 description 1
241000272525 Anas platyrhynchos Species 0.000 description 1
108010039627 Aprotinin Proteins 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
238000011729 BALB/c nude mouse Methods 0.000 description 1
235000021357 Behenic acid Nutrition 0.000 description 1
DPUOLQHDNGRHBS-UHFFFAOYSA-N Brassidinsaeure Natural products CCCCCCCCC=CCCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 1
101150013553 CD40 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229930105110 Cyclosporin A Natural products 0.000 description 1
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
108010036949 Cyclosporine Proteins 0.000 description 1
108010036941 Cyclosporins Proteins 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
206010012438 Dermatitis atopic Diseases 0.000 description 1
206010012442 Dermatitis contact Diseases 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
101100347633 Drosophila melanogaster Mhc gene Proteins 0.000 description 1
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
URXZXNYJPAJJOQ-UHFFFAOYSA-N Erucic acid Natural products CCCCCCC=CCCCCCCCCCCCC(O)=O URXZXNYJPAJJOQ-UHFFFAOYSA-N 0.000 description 1
UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
101001063392 Homo sapiens Lymphocyte function-associated antigen 3 Proteins 0.000 description 1
101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 1
101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
101000914496 Homo sapiens T-cell antigen CD7 Proteins 0.000 description 1
101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 1
101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
102100025390 Integrin beta-2 Human genes 0.000 description 1
102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 1
206010022680 Intestinal ischaemia Diseases 0.000 description 1
PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
UNXHWFMMPAWVPI-IMJSIDKUSA-N L-threitol Chemical compound OC[C@H](O)[C@@H](O)CO UNXHWFMMPAWVPI-IMJSIDKUSA-N 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
239000005639 Lauric acid Substances 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 description 1
102100030984 Lymphocyte function-associated antigen 3 Human genes 0.000 description 1
102000043136 MAP kinase family Human genes 0.000 description 1
108091054455 MAP kinase family Proteins 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-UHFFFAOYSA-N NVa2 cyclosporine Natural products CCCC1NC(=O)C(C(O)C(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-UHFFFAOYSA-N 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
239000005662 Paraffin oil Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 1
102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
206010063837 Reperfusion injury Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
101150054830 S100A6 gene Proteins 0.000 description 1
108060006706 SRC Proteins 0.000 description 1
102000001332 SRC Human genes 0.000 description 1
206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
206010049771 Shock haemorrhagic Diseases 0.000 description 1
206010041067 Small cell lung cancer Diseases 0.000 description 1
102000004584 Somatomedin Receptors Human genes 0.000 description 1
108010017622 Somatomedin Receptors Proteins 0.000 description 1
240000006394 Sorghum bicolor Species 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
230000006044 T cell activation Effects 0.000 description 1
102100027208 T-cell antigen CD7 Human genes 0.000 description 1
102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229910021626 Tin(II) chloride Inorganic materials 0.000 description 1
206010044541 Traumatic shock Diseases 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
102000005937 Tropomyosin Human genes 0.000 description 1
108010030743 Tropomyosin Proteins 0.000 description 1
102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
206010053648 Vascular occlusion Diseases 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
229930003427 Vitamin E Natural products 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
JIMXXGFJRDUSRO-UHFFFAOYSA-N adamantane-1-carboxylic acid Chemical compound C1C(C2)CC3CC2CC1(C(=O)O)C3 JIMXXGFJRDUSRO-UHFFFAOYSA-N 0.000 description 1
108091005764 adaptor proteins Proteins 0.000 description 1
102000035181 adaptor proteins Human genes 0.000 description 1
229960001456 adenosine triphosphate Drugs 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
210000000577 adipose tissue Anatomy 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
150000008041 alkali metal carbonates Chemical class 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
208000002029 allergic contact dermatitis Diseases 0.000 description 1
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
230000003321 amplification Effects 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000005349 anion exchange Methods 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
229940033495 antimalarials Drugs 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
201000008937 atopic dermatitis Diseases 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
239000002585 base Substances 0.000 description 1
229940116226 behenic acid Drugs 0.000 description 1
229940054066 benzamide antipsychotics Drugs 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000010609 cell counting kit-8 assay Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
238000002701 cell growth assay Methods 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000012292 cell migration Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
208000015114 central nervous system disease Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
230000008859 change Effects 0.000 description 1
WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
HNEGQIOMVPPMNR-IHWYPQMZSA-N citraconic acid Chemical compound OC(=O)C(/C)=C\C(O)=O HNEGQIOMVPPMNR-IHWYPQMZSA-N 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000010520 demethylation reaction Methods 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
239000003599 detergent Substances 0.000 description 1
238000011161 development Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
UKWLRLAKGMZXJC-QIECWBMSSA-L disodium;[4-chloro-3-[(3r,5s)-1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl]phenyl] phosphate Chemical compound [Na+].[Na+].O1OC2([C@@H]3CC4C[C@H]2CC(Cl)(C4)C3)C1(OC)C1=CC(OP([O-])([O-])=O)=CC=C1Cl UKWLRLAKGMZXJC-QIECWBMSSA-L 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
PXJJSXABGXMUSU-UHFFFAOYSA-N disulfur dichloride Chemical compound ClSSCl PXJJSXABGXMUSU-UHFFFAOYSA-N 0.000 description 1
229940116441 divinylbenzene Drugs 0.000 description 1
MYRTYDVEIRVNKP-UHFFFAOYSA-N divinylbenzene Substances C=CC1=CC=CC=C1C=C MYRTYDVEIRVNKP-UHFFFAOYSA-N 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
DPUOLQHDNGRHBS-KTKRTIGZSA-N erucic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCCCC(O)=O DPUOLQHDNGRHBS-KTKRTIGZSA-N 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
229940093471 ethyl oleate Drugs 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
229960005420 etoposide Drugs 0.000 description 1
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
238000000605 extraction Methods 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
239000010685 fatty oil Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229960002949 fluorouracil Drugs 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000001640 fractional crystallisation Methods 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
229960002584 gefitinib Drugs 0.000 description 1
239000000499 gel Substances 0.000 description 1
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
230000001434 glomerular Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000002343 gold Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
102000055193 human ZAP70 Human genes 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
239000005457 ice water Substances 0.000 description 1
229960002411 imatinib Drugs 0.000 description 1
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
238000003119 immunoblot Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000011261 inert gas Substances 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
201000002313 intestinal cancer Diseases 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229960004768 irinotecan Drugs 0.000 description 1
UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
208000001875 irritant dermatitis Diseases 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
229960002725 isoflurane Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000000842 isoxazolyl group Chemical group 0.000 description 1
206010023332 keratitis Diseases 0.000 description 1
201000010666 keratoconjunctivitis Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
238000002372 labelling Methods 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229940070765 laurate Drugs 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
230000007257 malfunction Effects 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
230000001394 metastastic effect Effects 0.000 description 1
206010061289 metastatic neoplasm Diseases 0.000 description 1
JHHMSRLTZAUMOJ-UHFFFAOYSA-N methanamine;oxolane Chemical compound NC.C1CCOC1 JHHMSRLTZAUMOJ-UHFFFAOYSA-N 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
SJJJFLXTGHEZJB-UHFFFAOYSA-N methyl 2-(bromomethyl)-6-nitrobenzoate Chemical compound COC(=O)C1=C(CBr)C=CC=C1[N+]([O-])=O SJJJFLXTGHEZJB-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
230000003641 microbiacidal effect Effects 0.000 description 1
229940124561 microbicide Drugs 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
238000010232 migration assay Methods 0.000 description 1
229950000844 mizoribine Drugs 0.000 description 1
229950007856 mofetil Drugs 0.000 description 1
238000003032 molecular docking Methods 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
230000004899 motility Effects 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
229940014456 mycophenolate Drugs 0.000 description 1
229960000951 mycophenolic acid Drugs 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000000651 myofibroblast Anatomy 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
KIJNOLBJCRWCNG-UHFFFAOYSA-N n-[5-bromo-2-(2,5-dimethoxyanilino)pyrimidin-4-yl]-n-(4-morpholin-4-ylphenyl)methanesulfonamide Chemical compound COC1=CC=C(OC)C(NC=2N=C(C(Br)=CN=2)N(C=2C=CC(=CC=2)N2CCOCC2)S(C)(=O)=O)=C1 KIJNOLBJCRWCNG-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
RMUZYFLUVBERQD-UHFFFAOYSA-N n-cyclobutyl-2-[(2,5-dichloropyrimidin-4-yl)amino]benzenesulfonamide Chemical compound ClC1=NC=C(Cl)C(NC=2C(=CC=CC=2)S(=O)(=O)NC2CCC2)=N1 RMUZYFLUVBERQD-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
230000018791 negative regulation of catalytic activity Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
208000014500 neuronal tumor Diseases 0.000 description 1
LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
MCSAJNNLRCFZED-UHFFFAOYSA-N nitroethane Chemical compound CC[N+]([O-])=O MCSAJNNLRCFZED-UHFFFAOYSA-N 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
238000013392 nude mouse xenograft model Methods 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
229910052763 palladium Inorganic materials 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
150000002960 penicillins Chemical class 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
229950000964 pepstatin Drugs 0.000 description 1
108010091212 pepstatin Proteins 0.000 description 1
FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
238000010647 peptide synthesis reaction Methods 0.000 description 1
VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
238000006303 photolysis reaction Methods 0.000 description 1
230000015843 photosynthesis, light reaction Effects 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
239000000049 pigment Substances 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 1
125000005936 piperidyl group Chemical group 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940116317 potato starch Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
201000001514 prostate carcinoma Diseases 0.000 description 1
208000023958 prostate neoplasm Diseases 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
239000001944 prunus armeniaca kernel oil Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
125000000168 pyrrolyl group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
238000007789 sealing Methods 0.000 description 1
208000008742 seborrheic dermatitis Diseases 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229960002930 sirolimus Drugs 0.000 description 1
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
208000000587 small cell lung carcinoma Diseases 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
239000012321 sodium triacetoxyborohydride Substances 0.000 description 1
VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
102000009076 src-Family Kinases Human genes 0.000 description 1
108010087686 src-Family Kinases Proteins 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
235000011150 stannous chloride Nutrition 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
229940124530 sulfonamide Drugs 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
208000013076 thyroid tumor Diseases 0.000 description 1
238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000009466 transformation Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000017105 transposition Effects 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
230000004565 tumor cell growth Effects 0.000 description 1
230000004614 tumor growth Effects 0.000 description 1
208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
208000021331 vascular occlusion disease Diseases 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
235000019165 vitamin E Nutrition 0.000 description 1
229940046009 vitamin E Drugs 0.000 description 1
239000011709 vitamin E Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

NO20054726A 2003-03-14 2005-10-13 2,4-di(fenylamino)pyrimidiner, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat innholdende en slik forbindelse NO331977B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GBGB0305929.2A GB0305929D0 (en)	2003-03-14	2003-03-14	Organic compounds
GB0319227A GB0319227D0 (en)	2003-08-15	2003-08-15	Organic compounds
GB0322370A GB0322370D0 (en)	2003-09-24	2003-09-24	Organic compounds
PCT/EP2004/002616 WO2004080980A1 (en)	2003-03-14	2004-03-12	2, 4- di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders

Publications (3)

Publication Number	Publication Date
NO20054726D0 NO20054726D0 (no)	2005-10-13
NO20054726L NO20054726L (no)	2005-12-08
NO331977B1 true NO331977B1 (no)	2012-05-14

Family

ID=32995437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20054726A NO331977B1 (no)	2003-03-14	2005-10-13	2,4-di(fenylamino)pyrimidiner, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat innholdende en slik forbindelse

Country Status (26)

Country	Link
US (2)	US7964592B2 (zh)
EP (2)	EP2275413B1 (zh)
JP (1)	JP4796487B2 (zh)
KR (1)	KR101148261B1 (zh)
CN (2)	CN1788001B (zh)
AT (1)	ATE497495T1 (zh)
AU (1)	AU2004220338B2 (zh)
BR (2)	BRPI0408347B8 (zh)
CA (1)	CA2518932C (zh)
CY (1)	CY1114238T1 (zh)
DE (1)	DE602004031287D1 (zh)
DK (1)	DK2275413T3 (zh)
EC (1)	ECSP056019A (zh)
ES (1)	ES2409885T3 (zh)
GB (1)	GB0305929D0 (zh)
IL (1)	IL170546A (zh)
IS (1)	IS2961B (zh)
MA (1)	MA27668A1 (zh)
MX (1)	MXPA05009883A (zh)
NO (1)	NO331977B1 (zh)
NZ (1)	NZ542219A (zh)
PL (2)	PL2275413T3 (zh)
PT (2)	PT1606265E (zh)
SI (1)	SI2275413T1 (zh)
TN (1)	TNSN05225A1 (zh)
WO (1)	WO2004080980A1 (zh)

Families Citing this family (321)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI329105B (en)	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
ES2445208T3 (es)	2002-07-29	2014-02-28	Rigel Pharmaceuticals, Inc.	Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
KR101201603B1 (ko)	2003-07-30	2012-11-14	리겔 파마슈티칼스, 인크.	자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
EP1663242B1 (en) *	2003-08-07	2011-04-27	Rigel Pharmaceuticals, Inc.	2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
MY147449A (en) *	2003-08-15	2012-12-14	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en)	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
JP2007505858A (ja) *	2003-09-18	2007-03-15	ノバルティスアクチエンゲゼルシャフト	増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
EP1598343A1 (de)	2004-05-19	2005-11-23	Boehringer Ingelheim International GmbH	2-Arylaminopyrimidine als PLK Inhibitoren
WO2005118543A1 (ja) *	2004-06-03	2005-12-15	Ono Pharmaceutical Co., Ltd.	キナーゼ阻害薬およびその用途
US7521457B2 (en) *	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
GB0419160D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
GB0419161D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
EP1814878B1 (en)	2004-11-24	2012-01-04	Rigel Pharmaceuticals, Inc.	Spiro-2, 4-pyrimidinediamine compounds and their uses
KR20070085433A (ko) *	2004-11-24	2007-08-27	노파르티스 아게	Ｊａｋ 저해제들과 ｂｃｒ-ａｂｌ, ｆｌｔ-3, ｆａｋ 또는ｒａｆ 키나제 저해제들 중 하나 이상의 조합물
ATE451381T1 (de)	2005-01-19	2009-12-15	Rigel Pharmaceuticals Inc	Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
KR20070097590A (ko) *	2005-01-25	2007-10-04	에픽스 델라웨어, 인코포레이티드	치환된 아릴아민 화합물 및 5―ｈｔ6 조절제로서의 이의용도
KR101386494B1 (ko)	2005-05-10	2014-04-24	인사이트 코포레이션	인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법
US20070203161A1 (en)	2006-02-24	2007-08-30	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the jak pathway
US7491732B2 (en)	2005-06-08	2009-02-17	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
WO2007028445A1 (en) *	2005-07-15	2007-03-15	Glaxo Group Limited	6-indolyl-4-yl-amino-5-halogeno-2-pyrimidinyl-amino derivatives
WO2007009681A1 (en) *	2005-07-15	2007-01-25	Glaxo Group Limited	1 , 1-DIOXID0-2 , 3-DIHYDRO-l , 2-BENZISOTHIAZ0L-6-YL-1H-INDAZOL-4-YL-2 , 4-PYRIMIDINEDI AMINE DERIVATIVES
US20070149506A1 (en)	2005-09-22	2007-06-28	Arvanitis Argyrios G	Azepine inhibitors of Janus kinases
PT1951684T (pt)	2005-11-01	2016-10-13	Targegen Inc	Inibidores de cinases de tipo biaril-meta-pirimidina
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
TWI468162B (zh)	2005-12-13	2015-01-11	英塞特公司	作為傑納斯激酶（ＪＡＮＵＳＫＩＮＡＳＥ）抑制劑之經雜芳基取代之吡咯并〔２，３-ｂ〕吡啶及吡咯并〔２，３-ｂ〕嘧啶
US20080318989A1 (en) *	2005-12-19	2008-12-25	Burdick Daniel J	Pyrimidine Kinase Inhibitors
WO2007085540A1 (en) *	2006-01-27	2007-08-02	Glaxo Group Limited	1h-indaz0l-4-yl-2 , 4-pyrimidinediamine derivatives
PL1984357T3 (pl)	2006-02-17	2014-03-31	Rigel Pharmaceuticals Inc	Związki 2,4-pirymidynodiaminy do leczenia lub zapobiegania chorób autoimmunologicznych
TW200804364A (en) *	2006-02-22	2008-01-16	Boehringer Ingelheim Int	New compounds
US8962643B2 (en)	2006-02-24	2015-02-24	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
EP2004632B1 (en) *	2006-03-30	2014-03-12	Janssen R&D Ireland	Hiv inhibiting 5-amido substituted pyrimidines
EP2447359B1 (en)	2006-04-14	2015-11-04	Cell Signaling Technology, Inc.	Gene defects and mutant ALK kinase in human solid tumors
US8168383B2 (en)	2006-04-14	2012-05-01	Cell Signaling Technology, Inc.	Gene defects and mutant ALK kinase in human solid tumors
US8623887B2 (en)	2006-05-15	2014-01-07	Boehringer Ingelheim International Gmbh	Compounds
BRPI0715418A2 (pt) *	2006-07-21	2013-03-26	Novartis Ag	compostos de 2,4-di(arilaminio)-pirimidina-5-carboxamida como inibidores de cinases jak
EP1914240B1 (en)	2006-10-11	2009-12-02	Astellas Pharma Inc.	EML4-ALK fusion gene
CA2598893C (en)	2006-10-11	2012-04-10	Astellas Pharma Inc.	Eml4-alk fusion gene
US8148391B2 (en) *	2006-10-23	2012-04-03	Cephalon, Inc.	Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors
BRPI0722384A2 (pt)	2006-12-08	2012-06-12	Irm Llc	compostos inibidores de proteÍna quinase, composiÇÕes contendo os mesmos bem como seus usos
EP2091918B1 (en)	2006-12-08	2014-08-27	Irm Llc	Compounds and compositions as protein kinase inhibitors
CA2670645A1 (en) *	2006-12-19	2008-07-03	Genentech, Inc.	Pyrimidine kinase inhibitors
ES2527696T3 (es) *	2006-12-21	2015-01-28	Nerviano Medical Sciences S.R.L.	Derivados de pirazoloquinazolina sustituidos, procedimientos para su preparación y su uso como inhibidores de la quinasa
US8513270B2 (en)	2006-12-22	2013-08-20	Incyte Corporation	Substituted heterocycles as Janus kinase inhibitors
CL2008000197A1 (es)	2007-01-26	2008-08-01	Smithkline Beecham Corp	Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
US7834024B2 (en)	2007-03-26	2010-11-16	Rigel Pharmaceuticals, Inc.	Compositions and methods for inhibition of the JAK pathway
CN101678215B (zh)	2007-04-18	2014-10-01	辉瑞产品公司	用于治疗异常细胞生长的磺酰胺衍生物
CL2008001709A1 (es)	2007-06-13	2008-11-03	Incyte Corp	Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
SG10201509887UA (en)	2007-06-13	2016-01-28	Incyte Corp	Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
TWI389893B (zh) *	2007-07-06	2013-03-21	Astellas Pharma Inc	二（芳胺基）芳基化合物
AU2008277446A1 (en) *	2007-07-16	2009-01-22	Astrazeneca Ab	Pyrimidine derivatives 934
EP2188292B1 (en) *	2007-08-08	2013-05-29	GlaxoSmithKline Intellectual Property Development Limited	2- [ (2-{phenylamino}-1h-pyrrolo [2, 3-d]pyrimidin-4-yl) amino]benzamide derivatives as igf-1r inhibitors for the treatment of cancer
EA017252B1 (ru) *	2007-08-28	2012-11-30	Айрм Ллк	Производные 2-бифениламино-4-аминопиримидина в качестве ингибиторов киназ
MY152948A (en)	2007-11-16	2014-12-15	Incyte Corp	4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
US8598172B2 (en)	2007-12-04	2013-12-03	Nerviano Medical Sciences S.R.L.	Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
ES2602577T3 (es)	2008-03-11	2017-02-21	Incyte Holdings Corporation	Derivados de azetidina y ciclobutano como inhibidores de JAK
CA2720946C (en) *	2008-04-07	2013-05-28	Irm Llc	Compounds and compositions as protein kinase inhibitors
WO2009127642A2 (en) *	2008-04-15	2009-10-22	Cellzome Limited	Use of lrrk2 inhibitors for neurodegenerative diseases
US8063058B2 (en)	2008-04-16	2011-11-22	Portola Pharmaceuticals, Inc.	Inhibitors of syk and JAK protein kinases
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
JP2011518836A (ja)	2008-04-24	2011-06-30	インサイト・コーポレイション	大環状化合物およびそれらのキナーゼ阻害剤としての使用
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
DK2300013T3 (en) *	2008-05-21	2017-12-04	Ariad Pharma Inc	PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS
BRPI0914927B8 (pt)	2008-06-17	2021-05-25	Astrazeneca Ab	composto, composição farmacêutica e uso de um composto
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
UY31929A (es)	2008-06-25	2010-01-05	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
ES2711249T3 (es) *	2008-06-27	2019-04-30	Celgene Car Llc	Compuestos de heteroarilo y usos de los mismos
US11351168B1 (en)	2008-06-27	2022-06-07	Celgene Car Llc	2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en)	2008-06-27	2012-12-25	Celgene Avilomics Research, Inc.	2,4-disubstituted pyrimidines useful as kinase inhibitors
KR101649548B1 (ko)	2008-07-08	2016-08-19	인사이트 홀딩스 코포레이션	인돌아민 ２,３-디옥시게나아제의 억제제로서의 １,２,５-옥사디아졸
CL2009001884A1 (es)	2008-10-02	2010-05-14	Incyte Holdings Corp	Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
TWI491605B (zh)	2008-11-24	2015-07-11	Boehringer Ingelheim Int	新穎化合物
AR074209A1 (es)	2008-11-24	2010-12-29	Boehringer Ingelheim Int	Derivados de pirimidina utiles para el tratamiento del cancer
US8765727B2 (en)	2009-01-23	2014-07-01	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
WO2010129053A2 (en) *	2009-05-05	2010-11-11	Dana Farber Cancer Institute	Egfr inhibitors and methods of treating disorders
EP3009428B1 (en)	2009-05-08	2018-02-21	Astellas Pharma Inc.	Diamino heterocyclic carboxamide compound
SG176111A1 (en)	2009-05-22	2011-12-29	Incyte Corp	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
EA025520B1 (ru)	2009-05-22	2017-01-30	Инсайт Холдингс Корпорейшн	N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
TW201100441A (en) *	2009-06-01	2011-01-01	Osi Pharm Inc	Amino pyrimidine anticancer compounds
CA2764653C (en)	2009-06-10	2018-01-02	Chugai Seiyaku Kabushiki Kaisha	Tetracyclic compounds
JP5677425B2 (ja)	2009-06-29	2015-02-25	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	Ｐｉ３ｋ阻害剤としてのピリミジノン
WO2011028685A1 (en)	2009-09-01	2011-03-10	Incyte Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8486902B2 (en)	2009-10-09	2013-07-16	Incyte Corporation	Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7H-pyrrolo[2,3-d] pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
US8680108B2 (en)	2009-12-18	2014-03-25	Incyte Corporation	Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011075643A1 (en)	2009-12-18	2011-06-23	Incyte Corporation	Substituted heteroaryl fused derivatives as pi3k inhibitors
JP5858434B2 (ja)	2010-02-18	2016-02-10	インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅＨｏｌｄｉｎｇｓＣｏｒｐｏｒａｔｉｏｎ	Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体
MX347851B (es)	2010-03-10	2017-05-16	Incyte Corp	Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
CA2796311A1 (en)	2010-04-14	2011-10-20	Incyte Corporation	Fused derivatives as pi3k.delta. inhibitors
BR122014024883A2 (pt)	2010-05-14	2019-08-20	Dana-Farber Cancer Institute, Inc.	Compostos no tratamento de neoplasia
CN103180318B (zh)	2010-05-14	2017-05-10	达那-法伯癌症研究所	雄性避孕组合物以及使用方法
MX354217B (es)	2010-05-14	2018-02-19	Dana Farber Cancer Inst Inc	Composiciones y metodos para el tratamiento de leucemia.
EP2574168B9 (en)	2010-05-21	2016-10-05	Incyte Holdings Corporation	Topical formulation for a jak inhibitor
US8927547B2 (en)	2010-05-21	2015-01-06	Noviga Research Ab	Pyrimidine derivatives
WO2011163195A1 (en)	2010-06-21	2011-12-29	Incyte Corporation	Fused pyrrole derivatives as pi3k inhibitors
US20120101108A1 (en)	2010-08-06	2012-04-26	Cell Signaling Technology, Inc.	Anaplastic Lymphoma Kinase In Kidney Cancer
MY160734A (en)	2010-08-10	2017-03-15	Celgene Avilomics Res Inc	Besylate salt of a btk inhibitor
TWI526441B (zh)	2010-08-20	2016-03-21	中外製藥股份有限公司	包含四環化合物的組成物
EP2635285B1 (en)	2010-11-01	2017-05-03	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
NZ710636A (en)	2010-11-01	2017-02-24	Celgene Avilomics Res Inc	Heterocyclic compounds and uses thereof
AU2010363329A1 (en)	2010-11-07	2013-05-09	Targegen, Inc.	Compositions and methods for treating myelofibrosis
EP2637502B1 (en)	2010-11-10	2018-01-10	Celgene CAR LLC	Mutant-selective egfr inhibitors and uses thereof
US9034884B2 (en)	2010-11-19	2015-05-19	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
WO2012068450A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
PL2646448T3 (pl)	2010-11-29	2017-12-29	OSI Pharmaceuticals, LLC	Makrocykliczne inhibitory kinazy
EP2655374B1 (en)	2010-12-20	2019-10-23	Incyte Holdings Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US8546443B2 (en)	2010-12-21	2013-10-01	Boehringer Ingelheim International Gmbh	Benzylic oxindole pyrimidines
WO2012106540A1 (en)	2011-02-02	2012-08-09	Irm Llc	Methods of using alk inhibitors
ES2691673T3 (es) *	2011-02-17	2018-11-28	Cancer Therapeutics Crc Pty Limited	Inhibidores de Fak
DK2675794T3 (da) *	2011-02-17	2019-05-06	Cancer Therapeutics Crc Pty Ltd	Selektive fak-inhibitorer
AU2012219395B2 (en)	2011-02-18	2017-05-25	Incyte Corporation	mTOR/JAK inhibitor combination therapy
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012127032A1 (en)	2011-03-24	2012-09-27	Chemilia Ab	Novel pyrimidine derivatives
US9126948B2 (en)	2011-03-25	2015-09-08	Incyte Holdings Corporation	Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
WO2012135800A1 (en) *	2011-04-01	2012-10-04	University Of Utah Research Foundation	Substituted n-phenylpyrimidin-2-amine analogs as inhibitors of the axl kinase
AU2012250517B2 (en)	2011-05-04	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
CA2839767A1 (en)	2011-06-20	2012-12-27	Incyte Corporation	Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
WO2013023119A1 (en)	2011-08-10	2013-02-14	Novartis Pharma Ag	JAK P13K/mTOR COMBINATION THERAPY
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
KR102507287B1 (ko)	2011-09-02	2023-03-07	인사이트 홀딩스 코포레이션	Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
TW201325593A (zh)	2011-10-28	2013-07-01	Celgene Avilomics Res Inc	治療布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶疾病或病症之方法
BR112014012396B1 (pt)	2011-11-23	2020-08-25	Portola Pharmaceuticals, Inc	inibidores de pirazina quinase, composição, método in vitro para inibição de quinase syk ou via de transdução de sinal, uso dos referidos inibidores e kit
US8791130B2 (en) *	2011-11-29	2014-07-29	Genentech, Inc.	Aminopyrimidine derivatives as LRRK2 modulators
ES2880109T3 (es)	2012-03-15	2021-11-23	Celgene Car Llc	Formas sólidas de un inhibidor de la cinasa del receptor del factor de crecimiento epidérmico
CA2866857C (en)	2012-03-15	2021-03-09	Celgene Avilomics Research, Inc.	Salts of an epidermal growth factor receptor kinase inhibitor
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
AU2013204563B2 (en)	2012-05-05	2016-05-19	Takeda Pharmaceutical Company Limited	Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9193733B2 (en)	2012-05-18	2015-11-24	Incyte Holdings Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
ME03300B (me)	2012-06-13	2019-07-20	Incyte Holdings Corp	Supsтituisana triciklična jedinjenja као inhibiтori fgfr
KR101446742B1 (ko) *	2012-08-10	2014-10-01	한국화학연구원	Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
SG10201704588XA (en)	2012-09-25	2017-07-28	Chugai Pharmaceutical Co Ltd	Ret inhibitor
CN103788066A (zh) *	2012-10-31	2014-05-14	韩冰	一类保护移植器官的化合物及其用途
MX2015005428A (es)	2012-11-01	2015-07-21	Incyte Corp	Derivados triciclicos fusionados de tiofeno como inhibidores de la cinasa janus (jak).
US9206166B2 (en) *	2012-11-06	2015-12-08	SHANGHAI iNSTITUTE OF MATERIA MEDICA ACADEMY OF SCIENCES	Certain protein kinase inhibitors
BR112015010663B1 (pt)	2012-11-15	2022-12-06	Incyte Holdings Corporation	Formas de dosagem oral de liberação sustentada, e uso de ruxolitinib ou de sal farmaceuticamente aceitável do mesmo
US9126950B2 (en)	2012-12-21	2015-09-08	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
KR20150119012A (ko)	2013-02-08	2015-10-23	셀진 아빌로믹스 리서치, 인코포레이티드	Erk 억제제 및 이의 용도
JP2016509045A (ja)	2013-02-22	2016-03-24	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	がんを治療し、薬剤耐性を防止する方法
TWI657090B (zh)	2013-03-01	2019-04-21	英塞特控股公司	吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途
CN105189509B (zh)	2013-03-06	2017-12-19	因赛特公司	用于制备jak抑制剂的方法及中间体
PT2970205T (pt)	2013-03-14	2019-08-26	Tolero Pharmaceuticals Inc	Inibidores da jak2 e da alk2 e métodos para a sua utilização
WO2014159392A1 (en)	2013-03-14	2014-10-02	Dana-Farber Cancer Institute, Inc.	Bromodomain binding reagents and uses thereof
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
DK2986610T5 (en)	2013-04-19	2018-12-10	Incyte Holdings Corp	BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
TR201905814T4 (tr)	2013-05-17	2019-05-21	Incyte Corp	Jak inhibitörü olarak bipirazol tuzu.
EP3019489A4 (en)	2013-07-11	2016-12-28	Betta Pharmaceuticals Co Ltd	MODULATORS OF TYROSINE KINASE PROTEIN AND METHODS OF USE
WO2015013635A2 (en)	2013-07-25	2015-01-29	Dana-Farber Cancer Institute, Inc.	Inhibitors of transcription factors and uses thereof
RS60469B1 (sr)	2013-08-07	2020-07-31	Incyte Corp	Dozni oblici sa produženim oslobađanjem za jak1 inhibitor
TW201529074A (zh)	2013-08-20	2015-08-01	Incyte Corp	在ｃ-反應蛋白含量較高之實體腫瘤患者中的存活益處
US9492471B2 (en)	2013-08-27	2016-11-15	Celgene Avilomics Research, Inc.	Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
RU2016122654A (ru)	2013-11-08	2017-12-14	Дана-Фарбер Кэнсер Инститьют, Инк.	Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
US9415049B2 (en)	2013-12-20	2016-08-16	Celgene Avilomics Research, Inc.	Heteroaryl compounds and uses thereof
JP2017504650A (ja)	2014-01-31	2017-02-09	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	ジアゼパン誘導体およびその使用
EP3099677A4 (en) *	2014-01-31	2017-07-26	Dana-Farber Cancer Institute, Inc.	Diaminopyrimidine benzenesulfone derivatives and uses thereof
WO2015117087A1 (en)	2014-01-31	2015-08-06	Dana-Farber Cancer Institute, Inc.	Uses of diazepane derivatives
US10231965B2 (en)	2014-02-20	2019-03-19	Ignyta, Inc.	Molecules for administration to ROS1 mutant cancer cells
CN106456653A (zh)	2014-02-28	2017-02-22	腾沙治疗公司	高胰岛素血症相关病症的治疗
KR101656382B1 (ko)	2014-02-28	2016-09-09	한국화학연구원	피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물
DK3110409T3 (en)	2014-02-28	2018-10-22	Incyte Corp	JAK1 INHIBITORS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
MX2020004398A (es)	2014-04-08	2022-06-06	Incyte Corp	Tratamiento de neoplasias malignas de linfocitos b mediante una combinacion de inhibidores de janus cinasa (jak) y fosfatidilinositol 3 cinasa (pi3k).
CN106458967A (zh)	2014-04-25	2017-02-22	中外制药株式会社	四环化合物的新结晶
CA2946518C (en)	2014-04-25	2022-07-26	Chugai Seiyaku Kabushiki Kaisha	Preparation containing tetracyclic compound at high dose
MA39987A (fr)	2014-04-30	2017-03-08	Incyte Corp	Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
WO2015184305A1 (en)	2014-05-30	2015-12-03	Incyte Corporation	TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CN105330698B (zh) *	2014-07-04	2019-05-28	齐鲁制药有限公司	螺环芳基磷氧化物和硫化物
EP3165530B1 (en)	2014-07-04	2018-12-05	Qilu Pharmaceutical Co., Ltd	Spirocyclic aryl phosphorus oxide and aryl phosphorus sulfide
US10106507B2 (en) *	2014-08-03	2018-10-23	H. Lee Moffitt Cancer Center and Research Insitute, Inc.	Potent dual BRD4-kinase inhibitors as cancer therapeutics
BR112017002369A2 (pt)	2014-08-08	2017-12-05	Dana Farber Cancer Inst Inc	derivados de diazepana e usos dos mesmos
TWI803187B (zh)	2014-08-08	2023-05-21	日商中外製藥股份有限公司	包含４環性化合物的非晶質體之固體分散體及製劑
CA2955077A1 (en)	2014-08-08	2016-02-11	Dana-Farber Cancer Institute, Inc.	Dihydropteridinone derivatives and uses thereof
DK3179858T3 (da)	2014-08-13	2019-07-22	Celgene Car Llc	Forme og sammensætninger af en ERK-inhibitor
WO2016029002A2 (en) *	2014-08-22	2016-02-25	Clovis Oncology, Inc.	Growth factor receptor inhibitors
US10266549B2 (en)	2014-08-25	2019-04-23	Salk Institute For Biological Studies	ULK1 inhibitors and methods using same
EP3202765B1 (en) *	2014-09-29	2020-03-25	Hainan Xuanzhu Pharma Co., Ltd.	Polycyclic anaplastic lymphoma kinase inhibitor
KR101633722B1 (ko)	2014-10-08	2016-06-28	한국화학연구원	4-(1-퍼롤-3,4-디카르복시아미드)피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
EA033325B1 (ru)	2014-10-27	2019-09-30	Тэнша Терапеутикс, Инк.	Ингибиторы бромодомена
CA2969540C (en)	2014-12-02	2023-03-21	Ignyta, Inc.	Combinations for the treatment of neuroblastoma
TWI752901B (zh)	2015-01-16	2022-01-21	日商中外製藥股份有限公司	合併用醫藥
JP6479490B2 (ja) *	2015-01-27	2019-03-06	東ソー・ファインケム株式会社	５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
US9586949B2 (en)	2015-02-09	2017-03-07	Incyte Corporation	Aza-heteroaryl compounds as PI3K-gamma inhibitors
CN105985317B (zh) *	2015-02-12	2018-09-18	正大天晴药业集团股份有限公司	一种色瑞替尼的制备方法及其中间体
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EA038045B1 (ru)	2015-02-20	2021-06-28	Инсайт Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
PE20180129A1 (es)	2015-02-27	2018-01-18	Incyte Corp	Sales de inhibidor de pi3k y procesos de preparacion
KR101772134B1 (ko) *	2015-04-14	2017-08-29	한국화학연구원	N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN106146468B (zh) *	2015-04-17	2020-12-01	杭州雷索药业有限公司	吡啶酮类蛋白激酶抑制剂
KR101653571B1 (ko)	2015-04-22	2016-09-05	한국화학연구원	4-(2-아미노-테트라하이드로나프탈렌닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
US9988401B2 (en)	2015-05-11	2018-06-05	Incyte Corporation	Crystalline forms of a PI3K inhibitor
US9732097B2 (en)	2015-05-11	2017-08-15	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US20160362424A1 (en)	2015-05-11	2016-12-15	Incyte Corporation	Salts of (s)-7-(1-(9h-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5h-thiazolo[3,2-a]pyrimidin-5-one
WO2016201370A1 (en)	2015-06-12	2016-12-15	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
CN104892526A (zh) *	2015-06-17	2015-09-09	药源药物化学（上海）有限公司	一种2,5-二氯-n-(2-(异丙基磺酰基)苯基)嘧啶-4-胺的制备方法
BR112018004618A2 (pt)	2015-09-11	2018-09-25	Dana-Farber Cancer Institute, Inc.	ciano tienotriazoldiazepinas e usos das mesmas
WO2017044792A1 (en)	2015-09-11	2017-03-16	Dana-Farber Cancer Institute, Inc.	Acetamide thienotriazoldiazepines and uses thereof
WO2017066428A1 (en)	2015-10-13	2017-04-20	H. Lee Moffitt Cancer Center & Research Institute, Inc.	Brd4-kinase inhibitors as cancer therapeutics
CN106699743B (zh) *	2015-11-05	2020-06-12	湖北生物医药产业技术研究院有限公司	嘧啶类衍生物及其用途
MA43169B1 (fr)	2015-11-06	2022-05-31	Incyte Corp	Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
SG10201913450PA (en)	2015-11-25	2020-03-30	Dana Farber Cancer Inst Inc	Bivalent bromodomain inhibitors and uses thereof
EP3389645A4 (en)	2015-12-18	2019-12-18	Ignyta, Inc.	COMBINATIONS FOR TREATING CANCER
CN106928275B (zh) *	2015-12-29	2020-10-02	齐鲁制药有限公司	螺环胺类芳基磷氧化合物的制备方法及其中间体和晶型
WO2017120194A1 (en)	2016-01-05	2017-07-13	Incyte Corporation	Pyridine and pyridimine compounds as pi3k-gamma inhibitors
CN107216319B (zh) *	2016-03-21	2021-10-08	中国科学院上海药物研究所	一种2，4-二氨基嘧啶类衍生物、其制备方法及用途
AR108875A1 (es)	2016-06-24	2018-10-03	Incyte Corp	COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g
CN106220608B (zh) *	2016-07-25	2018-11-27	安润医药科技（苏州）有限公司	二苯氨基嘧啶及三嗪化合物、其药用组合物及用途
KR101937529B1 (ko) *	2016-07-26	2019-01-14	한국화학연구원	신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
SG10201914030UA (en) *	2016-08-29	2020-03-30	Univ Michigan Regents	Aminopyrimidines as alk inhibitors
WO2018155947A1 (ko)	2017-02-24	2018-08-30	재단법인 대구경북첨단의료산업진흥재단	혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
CN106905303A (zh) *	2017-03-16	2017-06-30	北京师范大学	一类靶向fak的化合物和其标记物、及它们的制备方法和应用
IT201700047189A1 (it) *	2017-05-02	2018-11-02	Fondazione St Italiano Tecnologia	Composti e composizioni per il trattamento di cancro, disordini della retina e cardiomiopatie
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CN108689994A (zh) *	2017-07-01	2018-10-23	浙江同源康医药股份有限公司	用作alk激酶抑制剂的化合物及其应用
IL271759B2 (en)	2017-07-19	2024-01-01	Ignyta Inc	Pharmaceutical preparations that include anthraxtinib
RS64654B1 (sr)	2017-07-28	2023-10-31	Yuhan Corp	Proces za pripremu n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2- morfolinofenil)akrilamida reakcijom odgovarajućeg amina sa 3-halo-propionil hloridom
WO2019077506A1 (en)	2017-10-17	2019-04-25	Ignyta, Inc.	PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
LT3697789T (lt)	2017-10-18	2021-12-10	Incyte Corporation	Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
CN109836415B (zh) *	2017-11-29	2020-11-06	北京博远精准医疗科技有限公司	作为alk抑制剂的脲类化合物
US10596161B2 (en)	2017-12-08	2020-03-24	Incyte Corporation	Low dose combination therapy for treatment of myeloproliferative neoplasms
US20210009613A1 (en) *	2017-12-12	2021-01-14	Shenzhen Targetrx, Inc.	Arylphosphine oxides for inhibiting kinase activity
US11306079B2 (en)	2017-12-21	2022-04-19	Incyte Corporation	3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors
CN108047204A (zh) *	2018-01-08	2018-05-18	沈阳药科大学	2,4-二芳氨基嘧啶衍生物及其制备方法和应用
WO2019152374A1 (en)	2018-01-30	2019-08-08	Incyte Corporation	Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CN110092759A (zh) *	2018-01-31	2019-08-06	陆柯潮	作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物
CA3091339A1 (en)	2018-02-16	2019-08-22	Incyte Corporation	Jak1 pathway inhibitors for the treatment of cytokine-related disorders
CN112384515A (zh)	2018-02-27	2021-02-19	因赛特公司	作为a2a/a2b抑制剂的咪唑并嘧啶和***并嘧啶
IL277071B1 (en)	2018-03-08	2024-03-01	Incyte Corp	Aminopyrizine diol compounds as PI3K–y inhibitors
MX2022012285A (es)	2018-03-30	2023-08-15	Incyte Corp	Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
MX2020010437A (es)	2018-04-05	2021-01-29	Sumitomo Pharma Oncology Inc	Inhibidores de axl cinasa y uso de los mismos.
US11220510B2 (en)	2018-04-09	2022-01-11	Incyte Corporation	Pyrrole tricyclic compounds as A2A / A2B inhibitors
US11466004B2 (en)	2018-05-04	2022-10-11	Incyte Corporation	Solid forms of an FGFR inhibitor and processes for preparing the same
EA202092649A1 (ru)	2018-05-04	2021-06-21	Инсайт Корпорейшн	Соли ингибитора fgfr
MX2020012376A (es)	2018-05-18	2021-03-09	Incyte Corp	Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
WO2019227007A1 (en)	2018-05-25	2019-11-28	Incyte Corporation	Tricyclic heterocyclic compounds as sting activators
US11046658B2 (en)	2018-07-02	2021-06-29	Incyte Corporation	Aminopyrazine derivatives as PI3K-γ inhibitors
EP3818063A1 (en)	2018-07-05	2021-05-12	Incyte Corporation	Fused pyrazine derivatives as a2a / a2b inhibitors
CA3103995A1 (en)	2018-07-26	2020-01-30	Sumitomo Dainippon Pharma Oncology, Inc.	Methods for treating diseases associated with abnormal acvr1 expression and acvr1 inhibitors for use in the same
US11008344B2 (en)	2018-07-31	2021-05-18	Incyte Corporation	Tricyclic heteroaryl compounds as STING activators
US10875872B2 (en)	2018-07-31	2020-12-29	Incyte Corporation	Heteroaryl amide compounds as sting activators
CN110835320A (zh) *	2018-08-15	2020-02-25	江苏奥赛康药业有限公司	二氨基嘧啶类化合物及其应用
CA3107270A1 (en)	2018-09-04	2020-03-12	Chugai Seiyaku Kabushiki Kaisha	Method for producing tetracyclic compound
MA53561A (fr)	2018-09-05	2022-05-11	Incyte Corp	Formes cristallines d'un inhibiteur de phosphoinositide 3-kinase (pi3k)
AU2019348011A1 (en) *	2018-09-27	2021-02-11	Dana-Farber Cancer Institute, Inc.	Degradation of FAK or FAK and ALK by conjugation of FAK and ALK inhibitors with E3 ligase ligands and methods of use
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN111171017B (zh) *	2018-11-09	2021-12-24	天津大学	基于嘧啶的衍生物及其制备方法和应用
WO2020102198A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en)	2018-11-13	2020-05-22	Incyte Corporation	Substituted heterocyclic derivatives as pi3k inhibitors
US11161838B2 (en)	2018-11-13	2021-11-02	Incyte Corporation	Heterocyclic derivatives as PI3K inhibitors
US11596692B1 (en)	2018-11-21	2023-03-07	Incyte Corporation	PD-L1/STING conjugates and methods of use
US20220056049A1 (en)	2019-01-07	2022-02-24	Incyte Corporation	Heteroaryl amide compounds as sting activators
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶
WO2020168197A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
CA3130210A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Cyclin-dependent kinase 2 biomarkers and uses thereof
TW202100520A (zh)	2019-03-05	2021-01-01	美商英塞特公司	作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US20220143049A1 (en)	2019-03-21	2022-05-12	Onxeo	A dbait molecule in combination with kinase inhibitor for the treatment of cancer
US11919904B2 (en)	2019-03-29	2024-03-05	Incyte Corporation	Sulfonylamide compounds as CDK2 inhibitors
US11440914B2 (en)	2019-05-01	2022-09-13	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
TW202112377A (zh)	2019-06-10	2021-04-01	美商英塞特公司	藉由jak抑制劑局部治療白斑症
CN114302878A (zh)	2019-07-03	2022-04-08	大日本住友制药肿瘤公司	酪氨酸激酶非受体1(tnk1)抑制剂及其用途
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
CA3148776A1 (en)	2019-08-01	2021-02-04	Incyte Corporation	A dosing regimen for an ido inhibitor
MX2022001940A (es)	2019-08-14	2022-05-10	Incyte Corp	Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
CA3150766A1 (en)	2019-08-26	2021-03-04	Incyte Corporation	Triazolopyrimidines as a2a / a2b inhibitors
PE20221905A1 (es)	2019-10-11	2022-12-23	Incyte Corp	Aminas biciclicas como inhibidoras de la cdk2
IL291901A (en)	2019-10-14	2022-06-01	Incyte Corp	Bicyclyl heterocycles as fgr suppressors
JP2023506118A (ja)	2019-10-16	2023-02-15	インサイト・コーポレイション	皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
KR102168179B1 (ko) *	2019-10-31	2020-10-20	주식회사 온코빅스	암세포 성장 억제 효과를 나타내는 신규한 헤테로 고리 치환 피리미딘 유도체 및 그를 포함하는 약제학적 조성물
JP2023500906A (ja)	2019-11-08	2023-01-11	インサーム（インスティテュナシオナルドゥラサンテエドゥラルシェルシェメディカル）	キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法
JP7390487B2 (ja) *	2019-12-03	2023-12-01	サムジンファーマシューティカルカンパニー，リミテッド	焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体
KR20220131900A (ko)	2019-12-04	2022-09-29	인사이트 코포레이션	Fgfr 억제제의 유도체
WO2021113479A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021125803A1 (ko) *	2019-12-16	2021-06-24	한국화학연구원	신규한 피리미딘 유도체 및 이의 용도
BR112022011834A2 (pt) *	2019-12-16	2022-08-30	Korea Res Inst Chemical Tech	Derivado de pirimidina e uso do mesmo
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
JP2023516441A (ja)	2020-03-06	2023-04-19	インサイト・コーポレイション	Ａｘｌ／ｍｅｒ阻害剤及びｐｄ－１／ｐｄ－ｌ１阻害剤を含む併用療法
CN111233834B (zh) *	2020-03-09	2021-08-31	北京师范大学	一类靶向fak的化合物和其标记物、及它们的制备方法和应用
IL297165A (en)	2020-04-16	2022-12-01	Incyte Corp	Soysag tricyclic CRS inhibitors
WO2021231526A1 (en)	2020-05-13	2021-11-18	Incyte Corporation	Fused pyrimidine compounds as kras inhibitors
BR112022024632A2 (pt)	2020-06-02	2023-02-28	Incyte Corp	Processos para preparar um inibidor de jak1
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
CN111560013B (zh) *	2020-06-08	2023-04-07	中山大学	一种自噬抑制剂及其应用
WO2022047093A1 (en)	2020-08-28	2022-03-03	Incyte Corporation	Vinyl imidazole compounds as inhibitors of kras
CA3195357A1 (en)	2020-09-16	2022-03-24	Incyte Corporation	Topical treatment of vitiligo
US11767320B2 (en)	2020-10-02	2023-09-26	Incyte Corporation	Bicyclic dione compounds as inhibitors of KRAS
CN112390760B (zh) *	2020-10-15	2022-07-29	北京师范大学	靶向fak的化合物及其制备方法和应用
EP4259131A1 (en)	2020-12-08	2023-10-18	Incyte Corporation	Jak1 pathway inhibitors for the treatment of vitiligo
WO2022155941A1 (en)	2021-01-25	2022-07-28	Qilu Regor Therapeutics Inc.	Cdk2 inhibitors
CN113024454B (zh) *	2021-03-25	2022-09-09	浙江工业大学	一种布格替尼中间体的合成方法
CN113061117B (zh) *	2021-03-30	2023-02-10	长治学院	一种2-((5-氯-2-(4-吗啉甲基苯胺基)嘧啶-4-基)氨基)苯甲酰胺衍生物
WO2022206888A1 (en)	2021-03-31	2022-10-06	Qilu Regor Therapeutics Inc.	Cdk2 inhibitors and use thereof
JP2024513575A (ja)	2021-04-12	2024-03-26	インサイト・コーポレイション	Ｆｇｆｒ阻害剤及びネクチン－４標的化剤を含む併用療法
AR126102A1 (es)	2021-06-09	2023-09-13	Incyte Corp	Heterociclos tricíclicos como inhibidores de fgfr
US20230002384A1 (en)	2021-06-09	2023-01-05	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
KR20240032915A (ko)	2021-07-07	2024-03-12	인사이트 코포레이션	Kras의 저해제로서의 삼환식 화합물
CA3224841A1 (en)	2021-07-14	2023-01-19	Zhenwu Li	Tricyclic compounds as inhibitors of kras
US20230174555A1 (en)	2021-08-31	2023-06-08	Incyte Corporation	Naphthyridine compounds as inhibitors of kras
WO2023049697A1 (en)	2021-09-21	2023-03-30	Incyte Corporation	Hetero-tricyclic compounds as inhibitors of kras
US20230143938A1 (en)	2021-10-01	2023-05-11	Incyte Corporation	Pyrazoloquinoline kras inhibitors
AU2022367432A1 (en)	2021-10-14	2024-05-02	Incyte Corporation	Quinoline compounds as inhibitors of kras
TW202320792A (zh)	2021-11-22	2023-06-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｋｒａｓ抑制劑之組合療法
TW202329937A (zh)	2021-12-03	2023-08-01	美商英塞特公司	雙環胺ｃｋ１２抑制劑
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
US20230183251A1 (en)	2021-12-10	2023-06-15	Incyte Corporation	Bicyclic amines as cdk12 inhibitors
WO2023109751A1 (zh) *	2021-12-13	2023-06-22	希格生科（深圳）有限公司	嘧啶或吡啶类衍生物及其医药用途
US20230192722A1 (en)	2021-12-22	2023-06-22	Incyte Corporation	Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
TW202341982A (zh)	2021-12-24	2023-11-01	大陸商上海齊魯銳格醫藥研發有限公司	Ｃｄｋ２抑制劑及其用途
WO2023168686A1 (en)	2022-03-11	2023-09-14	Qilu Regor Therapeutics Inc.	Substituted cyclopentanes as cdk2 inhibitors
US20230279004A1 (en)	2022-03-07	2023-09-07	Incyte Corporation	Solid forms, salts, and processes of preparation of a cdk2 inhibitor
CN114716385B (zh) *	2022-04-08	2024-03-12	北京师范大学	靶向粘着斑激酶的化合物及制备方法和应用
CN114956977B (zh) *	2022-06-09	2024-03-26	朗捷睿(苏州)生物科技有限公司	一种联苯类化合物、药物组合物及其制备方法和应用
WO2023245053A1 (en)	2022-06-14	2023-12-21	Incyte Corporation	Solid forms of a jak inhibitor and process of preparing the same
WO2023250430A1 (en)	2022-06-22	2023-12-28	Incyte Corporation	Bicyclic amine cdk12 inhibitors
WO2024015731A1 (en)	2022-07-11	2024-01-18	Incyte Corporation	Fused tricyclic compounds as inhibitors of kras g12v mutants
WO2024030600A1 (en)	2022-08-05	2024-02-08	Incyte Corporation	Treatment of urticaria using jak inhibitors
CN115448906B (zh) *	2022-09-26	2024-04-02	深圳大学	一种2-苯胺基嘧啶类衍生物及其制备方法与应用
CN116942671B (zh) *	2023-06-19	2024-02-27	中国人民解放军空军军医大学	ALK inhibitor 2在制备治疗食管鳞癌的药物中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL129020C (zh)	1964-12-15
US3432493A (en)	1966-06-27	1969-03-11	Abbott Lab	Substituted sulfanilamides
US3367149A (en) *	1966-12-15	1968-02-06	Minnesota Mining & Mfg	Radiant white light source
GB9523675D0 (en)	1995-11-20	1996-01-24	Celltech Therapeutics Ltd	Chemical compounds
GB9619284D0 (en)	1996-09-16	1996-10-30	Celltech Therapeutics Ltd	Chemical compounds
GB9622363D0 (en)	1996-10-28	1997-01-08	Celltech Therapeutics Ltd	Chemical compounds
GB9705361D0 (en)	1997-03-14	1997-04-30	Celltech Therapeutics Ltd	Chemical compounds
EP1054004B1 (en) *	1997-12-15	2008-07-16	Astellas Pharma Inc.	Novel pyrimidine-5-carboxamide derivatives
ATE232521T1 (de)	1998-03-27	2003-02-15	Janssen Pharmaceutica Nv	Hiv hemmende pyrimidin derivate
DE69933680T2 (de)	1998-08-29	2007-08-23	Astrazeneca Ab	Pyrimidine verbindungen
GB9828511D0 (en) *	1998-12-24	1999-02-17	Zeneca Ltd	Chemical compounds
EP1184376B1 (en)	1999-06-09	2005-02-02	Yamanouchi Pharmaceutical Co. Ltd.	Novel heterocyclic carboxamide derivatives
JP2003511378A (ja)	1999-10-07	2003-03-25	アムジエン・インコーポレーテツド	トリアジン系キナーゼ阻害薬
CN1429222A (zh) *	2000-02-17	2003-07-09	安姆根有限公司	激酶抑制剂
US6376770B1 (en)	2000-02-28	2002-04-23	Douglas Hyde	Quick connecting universal electrical box and wiring system
GB0004887D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004888D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
GB0004890D0 (en)	2000-03-01	2000-04-19	Astrazeneca Uk Ltd	Chemical compounds
WO2002010689A1 (de) *	2000-08-02	2002-02-07	Continental Teves Ag & Co. Ohg	Aktiver magnetfeldsensor, dessen verwendung, verfahren und vorrichtung
US20020132823A1 (en)	2001-01-17	2002-09-19	Jiahuai Han	Assay method
US6939874B2 (en) *	2001-08-22	2005-09-06	Amgen Inc.	Substituted pyrimidinyl derivatives and methods of use
WO2003030909A1 (en) *	2001-09-25	2003-04-17	Bayer Pharmaceuticals Corporation	2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
TWI329105B (en) *	2002-02-01	2010-08-21	Rigel Pharmaceuticals Inc	2,4-pyrimidinediamine compounds and their uses
WO2003066601A1 (en)	2002-02-08	2003-08-14	Smithkline Beecham Corporation	Pyrimidine compounds
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
AU2003231231A1 (en)	2002-05-06	2003-11-11	Bayer Pharmaceuticals Corporation	Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
MXPA04012855A (es)	2002-06-28	2005-04-19	Yamanouchi Pharma Co Ltd	Derivado de diaminopirimidincarboxiamida.
UA80767C2 (en)	2002-12-20	2007-10-25	Pfizer Prod Inc	Pyrimidine derivatives for the treatment of abnormal cell growth
ES2325440T3 (es)	2003-02-20	2009-09-04	Smithkline Beecham Corporation	Compuestos de pirimidina.
GB0305929D0 (en)	2003-03-14	2003-04-23	Novartis Ag	Organic compounds
MY147449A (en)	2003-08-15	2012-12-14	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0321710D0 (en)	2003-09-16	2003-10-15	Novartis Ag	Organic compounds
JP2007505858A (ja)	2003-09-18	2007-03-15	ノバルティスアクチエンゲゼルシャフト	増殖性障害の処置に有用な２，４−ジ（フェニルアミノ）ピリミジン
US7521457B2 (en) *	2004-08-20	2009-04-21	Boehringer Ingelheim International Gmbh	Pyrimidines as PLK inhibitors
GB0419160D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
EP1814878B1 (en)	2004-11-24	2012-01-04	Rigel Pharmaceuticals, Inc.	Spiro-2, 4-pyrimidinediamine compounds and their uses

2003
- 2003-03-14 GB GBGB0305929.2A patent/GB0305929D0/en not_active Ceased
2004
- 2004-03-12 MX MXPA05009883A patent/MXPA05009883A/es active IP Right Grant
- 2004-03-12 DK DK10009414.3T patent/DK2275413T3/da active
- 2004-03-12 BR BRPI0408347A patent/BRPI0408347B8/pt active IP Right Grant
- 2004-03-12 AT AT04719989T patent/ATE497495T1/de active
- 2004-03-12 BR BR122019010008A patent/BR122019010008B8/pt active IP Right Grant
- 2004-03-12 EP EP10009414A patent/EP2275413B1/en not_active Expired - Lifetime
- 2004-03-12 NZ NZ542219A patent/NZ542219A/en not_active IP Right Cessation
- 2004-03-12 PL PL10009414T patent/PL2275413T3/pl unknown
- 2004-03-12 CA CA2518932A patent/CA2518932C/en not_active Expired - Lifetime
- 2004-03-12 US US10/549,250 patent/US7964592B2/en active Active
- 2004-03-12 PL PL04719989T patent/PL1606265T3/pl unknown
- 2004-03-12 PT PT04719989T patent/PT1606265E/pt unknown
- 2004-03-12 WO PCT/EP2004/002616 patent/WO2004080980A1/en active Application Filing
- 2004-03-12 JP JP2006504673A patent/JP4796487B2/ja not_active Expired - Lifetime
- 2004-03-12 SI SI200432034T patent/SI2275413T1/sl unknown
- 2004-03-12 CN CN2004800130419A patent/CN1788001B/zh not_active Expired - Lifetime
- 2004-03-12 CN CN2010102347117A patent/CN101921236B/zh not_active Expired - Lifetime
- 2004-03-12 KR KR1020057017082A patent/KR101148261B1/ko active Protection Beyond IP Right Term
- 2004-03-12 EP EP04719989A patent/EP1606265B1/en not_active Expired - Lifetime
- 2004-03-12 ES ES10009414T patent/ES2409885T3/es not_active Expired - Lifetime
- 2004-03-12 PT PT100094143T patent/PT2275413E/pt unknown
- 2004-03-12 DE DE602004031287T patent/DE602004031287D1/de not_active Expired - Lifetime
- 2004-03-12 AU AU2004220338A patent/AU2004220338B2/en not_active Expired
2005
- 2005-08-29 IL IL170546A patent/IL170546A/en active IP Right Grant
- 2005-09-13 TN TNP2005000225A patent/TNSN05225A1/en unknown
- 2005-09-14 EC EC2005006019A patent/ECSP056019A/es unknown
- 2005-09-23 MA MA28510A patent/MA27668A1/fr unknown
- 2005-10-06 IS IS8062A patent/IS2961B/is unknown
- 2005-10-13 NO NO20054726A patent/NO331977B1/no unknown
2011
- 2011-04-27 US US13/095,760 patent/US8263590B2/en not_active Expired - Fee Related
2013
- 2013-05-27 CY CY20131100414T patent/CY1114238T1/el unknown

Also Published As

Publication number	Publication date
WO2004080980A1 (en)	2004-09-23
BR122019010008B1 (pt)	2019-09-17
DK2275413T3 (da)	2013-06-03
NO20054726D0 (no)	2005-10-13
JP2006520354A (ja)	2006-09-07
BRPI0408347B1 (pt)	2019-08-06
CA2518932C (en)	2012-12-04
IS8062A (is)	2005-10-06
US20060247241A1 (en)	2006-11-02
EP2275413B1 (en)	2013-03-06
KR20050109987A (ko)	2005-11-22
ES2409885T3 (es)	2013-06-28
AU2004220338B2 (en)	2008-10-09
BR122019010008B8 (pt)	2021-07-27
TNSN05225A1 (en)	2007-06-11
EP2275413A1 (en)	2011-01-19
NO20054726L (no)	2005-12-08
BRPI0408347A (pt)	2006-03-21
PL1606265T3 (pl)	2011-07-29
BRPI0408347B8 (pt)	2021-05-25
NZ542219A (en)	2009-01-31
GB0305929D0 (en)	2003-04-23
KR101148261B1 (ko)	2012-05-21
PL2275413T3 (pl)	2013-08-30
US7964592B2 (en)	2011-06-21
ATE497495T1 (de)	2011-02-15
ECSP056019A (es)	2006-01-27
US8263590B2 (en)	2012-09-11
CY1114238T1 (el)	2016-08-31
CN101921236B (zh)	2013-01-16
CN1788001B (zh)	2010-09-22
CN1788001A (zh)	2006-06-14
PT1606265E (pt)	2011-05-05
SI2275413T1 (sl)	2013-07-31
JP4796487B2 (ja)	2011-10-19
EP1606265A1 (en)	2005-12-21
PT2275413E (pt)	2013-06-21
MXPA05009883A (es)	2005-12-05
EP1606265B1 (en)	2011-02-02
IL170546A (en)	2013-12-31
DE602004031287D1 (de)	2011-03-17
US20110201606A1 (en)	2011-08-18
AU2004220338A1 (en)	2004-09-23
MA27668A1 (fr)	2005-12-01
CN101921236A (zh)	2010-12-22
CA2518932A1 (en)	2004-09-23
IS2961B (is)	2017-02-15

Publication	Publication Date	Title
NO331977B1 (no)	2012-05-14	2,4-di(fenylamino)pyrimidiner, fremgangsmate for fremstilling derav, anvendelse derav samt farmasoytisk preparat innholdende en slik forbindelse
JP4607879B2 (ja)	2011-01-05	新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン
AU2005276582B2 (en)	2009-07-16	Pyrimidine derivatives
KR100894349B1 (ko)	2009-04-22	피리미딘 유도체